Uplizna: Expiry of patents in US related to CD19 antibodies and pharmaceutical compositions on Mar 07, 2030 (Amgen) - Feb 17, 2024 - Annual Report 2023: Expiry of patents in EU related to CD19 antibodies, pharmaceutical compositions and methods of treatment on Sep 07, 2027, SPC in Italy and Spain until 2032
Patent • Immune Modulation • Immunology • Inflammation • Neuromyelitis Optica Spectrum Disorder • Systemic Sclerosis
|